Supemtek® + Vaxigriptetra®
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Morbid Obesity
Conditions
Morbid Obesity, Severe Obesity
Trial Timeline
Nov 7, 2022 → Oct 3, 2023
NCT ID
NCT05409612About Supemtek® + Vaxigriptetra®
Supemtek® + Vaxigriptetra® is a phase 3 stage product being developed by Sanofi for Morbid Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05409612. Target conditions include Morbid Obesity, Severe Obesity.
What happened to similar drugs?
3 of 4 similar drugs in Morbid Obesity were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05409612 | Phase 3 | Completed |
Competing Products
7 competing products in Morbid Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 43 |
| Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg | Merck | Approved | 43 |
| Rocuronium | Merck | Approved | 43 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 47 |
| Molindone | Supernus Pharmaceuticals | Phase 2 | 29 |
| SPN-810M | Supernus Pharmaceuticals | Phase 1 | 23 |
| SPN-810 + Placebo | Supernus Pharmaceuticals | Phase 2 | 29 |